The NLRP3 inflammasome: an emerging therapeutic target for chronic pain

J Neuroinflammation. 2021 Mar 30;18(1):84. doi: 10.1186/s12974-021-02131-0.

Abstract

Chronic pain affects the life quality of the suffering patients and posts heavy problems to the health care system. Conventional medications are usually insufficient for chronic pain management and oftentimes results in many adverse effects. The NLRP3 inflammasome controls the processing of proinflammatory cytokine interleukin 1β (IL-1β) and is implicated in a variety of disease conditions. Recently, growing number of evidence suggests that NLRP3 inflammasome is dysregulated under chronic pain condition and contributes to pathogenesis of chronic pain. This review provides an up-to-date summary of the recent findings of the involvement of NLRP3 inflammasome in chronic pain and discussed the expression and regulation of NLRP3 inflammasome-related signaling components in chronic pain conditions. This review also summarized the successful therapeutic approaches that target against NLRP3 inflammasome for chronic pain treatment.

Keywords: Caspase-1; Inflammasome; Inflammation; Interleukins; NLRP3; Pain.

Publication types

  • Review

MeSH terms

  • Animals
  • Chronic Pain / drug therapy*
  • Chronic Pain / metabolism*
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Furans / administration & dosage*
  • Humans
  • Indenes / administration & dosage*
  • NLR Family, Pyrin Domain-Containing 3 Protein / antagonists & inhibitors
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism*
  • Sulfonamides / administration & dosage*

Substances

  • Furans
  • Indenes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human
  • Sulfonamides
  • N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide